Internal records say EPA scientists completed a PFNA toxicity assessment in April that found links to lower birth weight, liver injury, and male reproductive harms, and calculated safe‑exposure levels. Yet the report hasn’t been published while the agency moves to reconsider PFAS drinking‑water limits. With PFNA found in systems serving roughly 26 million people, nonrelease functions as a policy lever.
— It shows how withholding completed science can be used to advance deregulatory moves, undermining evidence‑based policy and public trust on a major drinking‑water issue.
Chris Bowling
2026.04.15
55% relevant
Though about a different contaminant, that existing idea flags agency delay or suppression of toxicology findings; the Omaha story similarly implicates regulatory and public‑health lapses—decades of smelter pollution and a massive residential cleanup paired with inadequate downstream testing—illustrating a pattern of regulatory‑system shortcomings in addressing chemical exposure risks.
BeauHD
2026.04.03
80% relevant
Both stories concern the EPA's handling of emerging chemical contaminants (PFNA/PFAS in the earlier item and microplastics/pharmaceuticals here). This article extends that thread by showing the agency is now formally treating microplastics and pharmaceuticals as candidate contaminants, signaling renewed scrutiny and potential regulatory action similar to the PFAS saga.
Matthew Yglesias
2026.03.04
70% relevant
Both stories expose how environmental and public‑health harms (toxic chemical exposures) can be created or ignored amid policy and regulatory choices; the CGD estimate of millions of tons of unsafe lead‑acid waste parallels the EPA item’s theme that agency science and action (or inaction) shape population exposures.
BeauHD
2026.01.13
90% relevant
Both stories document the EPA using internal processes to deprioritize or withhold scientific health evidence from rulemaking: the PFNA piece shows a completed toxicity assessment withheld from publication, and this article shows the agency moving to exclude quantified lives‑saved from benefit tallies — together they form a pattern of sidelining health evidence in regulatory choices.
by Sharon Lerner
2025.10.09
100% relevant
An internal EPA document stating the PFNA assessment was “completed and ready to post” in mid‑April, followed by a May announcement to rescind PFAS limits.